Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 1,743 trials

Vitiligo Treatment: Targeting TYK2 Responses

We are exploring a new treatment aimed at improving skin color in people with vitiligo. This study will help us understand if targeting specific responses can be beneficial.

Vitiligo>2 yearsEfficacy phase (II)Dermatology

Acute Myeloid Leukemia: Decitabine and Venetoclax with ATRA

We are studying whether adding all-trans retinoic acid to a treatment regimen helps patients with acute myeloid leukemia who cannot receive standard chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesHematologyOncology

Penile Rehabilitation After Prostate Cancer Surgery: PEHAB II

We are studying two approaches to help men regain erections after nerve-sparing prostate surgery. The goal is to see which method leads to better sexual function and quality of life.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteUrology

Castration-Resistant Prostate Cancer: Darolutamide with Radiation Therapy

We are studying whether adding stereotactic radiation therapy to darolutamide helps patients with castration-resistant prostate cancer and a few metastases live longer without disease progression. We will also evaluate the treatment's safety and impact on quality of life.

Castration-Resistant Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Advanced Prostate Cancer: 225Ac-PSMA-Trillium Study

We are testing a new treatment for men with advanced metastatic castration-resistant prostate cancer. This study aims to see how well it works and its safety in humans.

Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Oncology

Lung Cancer Treatment: Entrectinib vs. Crizotinib

We are comparing the effectiveness and safety of two medications for patients with advanced non-small cell lung cancer that has a specific genetic change. This study includes individuals with and without brain metastases.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Ulcerative Colitis: GRT-001 Treatment Study

We are evaluating a new treatment for ulcerative colitis in healthy volunteers and patients. The study aims to understand its safety and how it works in the body.

Ulcerative Colitis>2 yearsSafety phase (I)GastroenterologyInternal Medicine

Asciminib Roll-over Study for Leukemia Patients

We are examining the long-term safety of asciminib in patients with certain types of leukemia who have completed a previous study. This trial aims to see if continued treatment is beneficial for these patients.

Chronic Myeloid Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Advanced Tumor Cancer: ABBV-CLS-484 Treatment

We are studying a new treatment called ABBV-CLS-484 for people with advanced tumor cancer. The trial will explore its effects alone and in combination with other therapies.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Extracranial Malignant Germ Cell Tumors: Carboplatin vs. Cisplatin

We are comparing the effectiveness and side effects of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumors. This study aims to improve treatment options and patient quality of life.

Malignant Extracranial Germ Cell Tumours>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Asthma and COPD: GB-0895 Study

We are investigating the safety of a new drug, GB-0895, in patients with mild to moderate asthma and those with COPD. This study aims to understand how well the drug is tolerated in these groups.

Mild to Moderate AsthmaChronic Obstructive Pulmonary Disease (COPD)>2 yearsSafety phase (I)Pulmonology

Systemic Lupus Erythematosus: CABA-201 T Cell Therapy

We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyRheumatology

Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

Multiple Sclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Chronic Lymphocytic Leukemia: ABBV-453 Study

We are assessing how the oral medication ABBV-453 affects adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study focuses on understanding its side effects and how it moves through the body.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma>2 yearsSafety phase (I)Oncology

HER3-DXd for Advanced Solid Tumors

We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.

Locally Advanced or Metastatic Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Breast Imaging: Iodine Contrast Study

We are investigating how effective and safe iodine-based contrast agents are in enhancing mammograms and breast MRIs. This study aims to improve imaging quality for women undergoing these tests.

Breast Cancer>2 yearsConfirmation phase (III)Oncology

MB-CART19.1 for Refractory Systemic Lupus Erythematosus

We are testing a new treatment for patients with systemic lupus erythematosus that has not responded to standard therapies. The goal is to see if this new approach can provide better outcomes.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)Rheumatology

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Inclusion Body Myositis: Ruxolitinib Treatment Study

We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.

Inclusion Body Myositis>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Chronic Myeloid Leukemia: TERN-701 Treatment

We are evaluating a new treatment called TERN-701 for individuals with chronic myeloid leukemia. The study aims to assess its safety and how well it works compared to existing options.

Chronic Myeloid Leukemia>2 yearsSafety phase (I)Oncology